Evan Seigerman is ranked #1107 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Evan Seigerman (BMO Capital) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Evan Seigerman's stock ratings?

About 54% of Evan's ratings were profitable over a one-year hold, with an average return of +4.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Evan Seigerman

BMO

Evan Seigerman

BMO Capital

Wall Street Analyst

★★★☆☆

#1107

on 13Foresight · ranked by our own returns

53%

Success Rate

+4.4%

Average Return

32 of 60 calls profitable · -0.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 53% of Evan Seigerman's ratings turned a profit when each position was held for 1 year — averaging +4.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

182 Buy 83 Hold 15 Sell

Evan's Stock Coverage 36 ratings · 2026-07-15

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
AMGN Amgen	Jul 13, 2026	BUY	Buy -16.1% avg upside 57 analysts	$400.00 12.54% Upside	-1.4%
SDGR Schrodinger	Jul 13, 2026	BUY	Strong Buy +74.5% avg upside 14 analysts	$24.00 48.82% Upside	·
BNTX BioNTech SE	Jul 13, 2026	BUY	Strong Buy +51.1% avg upside 26 analysts	$128.00 41.55% Upside	·
ABBV AbbVie	Jul 13, 2026	BUY	Strong Buy -4.5% avg upside 46 analysts	$300.00 22.51% Upside	-0.3%
VRTX Vertex Pharmaceuticals	Jul 13, 2026	BUY	Strong Buy -6.8% avg upside 62 analysts	$600.00 25.93% Upside	·
REGN Regeneron	Jul 13, 2026	BUY	Strong Buy +17.3% avg upside 58 analysts	$730.00 11.16% Upside	-1.1%
PFE Pfizer	Jul 13, 2026	BUY	Buy +37.9% avg upside 45 analysts	$30.00 23.77% Upside	-0.9%
NVO Novo Nordisk	Jul 13, 2026	HOLD	Buy +136.2% avg upside 26 analysts	$45.00 8.33% Downside	·
NBIX Neurocrine	Jul 13, 2026	HOLD	Strong Buy +2.4% avg upside 37 analysts	$170.00 1.22% Downside	·
MRK Merck & Company	Jul 13, 2026	BUY	Strong Buy +6.5% avg upside 43 analysts	$142.00 17.54% Upside	-2.7%
INCY Incyte	Jul 13, 2026	HOLD	Buy -12.0% avg upside 47 analysts	$112.00 2.57% Downside	·
GILD Gilead Sciences	Jul 13, 2026	BUY	Strong Buy -8.5% avg upside 66 analysts	$174.00 33.74% Upside	+0.0%
LLY Eli Lilly & Co	Jul 13, 2026	BUY	Strong Buy -10.6% avg upside 47 analysts	$1300.00 12.54% Upside	+0.0%
BMY Bristol-Myers Squibb	Jul 13, 2026	HOLD	Buy +2.4% avg upside 42 analysts	$60.00 5.35% Upside	-4.0%
BIIB Biogen	Jul 13, 2026	HOLD	Strong Buy +27.2% avg upside 52 analysts	$196.00 2.05% Upside	·
TSE:APTX Apotex Health Corp.	Jul 06, 2026	BUY	Strong Buy +3.7% avg upside 10 analysts	$39.00 2.57% Upside	·
REPL Replimune Group	Jun 30, 2026	BUY	Buy +107.6% avg upside 13 analysts	$16.00 62.16% Upside	+0.4%
TSHA Taysha Gene Therapies	Jun 30, 2026	BUY	Strong Buy +142.4% avg upside 21 analysts	$14.00 145.65% Upside	-6.9%
ABCL AbCellera Biologics	Jun 17, 2026	BUY	Strong Buy +97.7% avg upside 15 analysts	$7.00 3.85% Upside	-7.1%
GPCR Structure Therapeutics, Inc. Sponsored ADR	Jun 05, 2026	BUY	Strong Buy +104.3% avg upside 17 analysts	$145.00 186.63% Upside	+2.7%
IRON Disc Medicine	Jun 02, 2026	BUY	Strong Buy +13.4% avg upside 21 analysts	$100.00 33.32% Upside	+19.1%
ACAD ACADIA Pharmaceuticals	May 11, 2026	BUY	Strong Buy +41.5% avg upside 42 analysts	$34.00 33.34% Upside	+19.7%
SRRK Scholar Rock Holding	Mar 18, 2026	BUY	Strong Buy +5.3% avg upside 23 analysts	$70.00 30.17% Upside	+42.5%
PTGX Protagonist Therapeutics	Oct 13, 2025	BUY	Strong Buy -29.1% avg upside 19 analysts	$112.00 14.59% Downside	+65.8%
ARVN Arvinas Holding Company	Sep 30, 2025	HOLD	Strong Buy +239.4% avg upside 27 analysts	—	-2.9%
NGNE Neurogene	Sep 30, 2025	HOLD	Strong Buy +26.7% avg upside 23 analysts	—	+59.9%
CCCC C4 Therapeutics	May 06, 2025	HOLD	Strong Buy +364.0% avg upside 19 analysts	—	+107.8%
DE:MRK Merck KGaA	Oct 23, 2024	BUY	Buy -2.5% avg upside 33 analysts	$131.70 5.58% Downside	·
CADL Candel Therapeutics	Aug 07, 2023	HOLD	Strong Buy +82.8% avg upside 11 analysts	—	+369.2%
NUVB Nuvation Bio	May 09, 2023	HOLD	Strong Buy +117.0% avg upside 15 analysts	—	+106.8%
IMA ImageneBio	Aug 13, 2021	BUY	Buy +178.6% avg upside 12 analysts	$27.00 348.52% Upside	-51.6%
GRTX Galera Therapeutics	Dec 16, 2020	BUY	Buy +6645.1% avg upside 7 analysts	$15.00 16945.41% Upside	·
NL:LKFT Galapagos	Oct 16, 2020	HOLD	Sell +103.2% avg upside 16 analysts	$129.00 400.81% Upside	·
TLPH Talphera	Aug 13, 2020	SELL	Strong Buy +236.1% avg upside 15 analysts	$0.84 40.25% Downside	+5.7%
MGNX MacroGenics	May 11, 2020	BUY	Buy +304.7% avg upside 25 analysts	$30.00 599.29% Upside	+16.1%
LKFT Lakefront Biotherapeutics	Feb 24, 2020	HOLD	Buy +258.4% avg upside 24 analysts	$220.00 646.51% Upside	·

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Evan Seigerman — Frequently Asked Questions

How accurate are Evan Seigerman's stock ratings?

Based on the calls 13Foresight could measure, about 54% of Evan's ratings were profitable over a one-year hold, with an average return of +4.6% per rating, or -0.3% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Evan ranked on 13Foresight?

Evan Seigerman is currently ranked #1107 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Evan cover?

Evan most recently has ratings on AMGN, SDGR, BNTX, ABBV, VRTX, REGN, PFE, NVO, NBIX, MRK, INCY, GILD and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!